Skip to main content
Molecular Cancer logoLink to Molecular Cancer
. 2021 Jun 15;20:92. doi: 10.1186/s12943-021-01378-8

Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

Qingjun Liu 1,2, James W Mier 1, David J Panka 1,
PMCID: PMC8204411  PMID: 34130704

Retraction Note to: Mol Cancer 10, 115 (2011)

https://doi.org/10.1186/1476-4598-10-115

The Editor-in-Chief has retracted this article after an investigation by Harvard Medical School and Beth Israel Deaconess Medical Center and additional analysis by the Office of Research Integrity found:

  • Reuse and relabelling of the same source bands to falsely represent different experimental results in Figure 3A (first four lanes in the middle row of the left panel representing c-myc expression in nucleus of A375 cell type, and first four lanes in the middle row of the right panel representing c-myc expression in nucleus of SK MEL 5 cell type)

  • Reuse and relabelling of the same source bands to falsely represent different experimental results in Figure 5 (sixth to eighth lanes of the middle row representing BCL-XL expression in A375-GSK cells with DOX, and last three lanes of the middle row representing BCL-XL expression in SK MEL 5 S9A)

  • Reuse and relabelling of unrelated source bands falsely represent different experimental results in Figure 5 (thirteenth to fifteenth lanes of the top row representing BCL2 expression in SK MEL 5 S9A, and thirteenth to fifteenth lanes of the bottom row representing VINCULIN expression in SK MEL 5 S9A)

James W Mier agrees with this retraction. David J Panka does not agree with this retraction. The Editor-in-Chief has not been able to find a current email address for Qingjun Liu.


Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES